Scott Douglas Christensen, M.D.

Philosophy of Care
Dr. Christensen believes in high quality, innovative, and compassionate care of his patients. Dr. Christensen believes in a team-based approach to patient care, utilizing expertise of nurses, pharmacists, social workers, and consultants to provide complete care for his patients.

Clinical Interests
Scott D. Christensen specializes in treating breast cancer, melanomas, sarcomas, and AIDS-related malignancies. He also serves as medical director for the UC Davis Inpatient Hem/Onc unit.

Title
Professor of Medicine

Specialty
Breast Cancer, Sarcoma, Hospice and Palliative Medicine, Hematology/Oncology, Internal Medicine

Department
Internal Medicine

Division
Hematology and Oncology

Center/Program Affiliation
UC Davis Comprehensive Cancer Center

Address/Phone
UC Davis Comprehensive Cancer Center, 2279 45th Street Sacramento, CA 95817
Phone: 916-734-5959

Additional Phone
Clinic Fax: 916-703-5265
Clinic Referral Phone: 916-703-5210
Physician Referrals: 800-4-UCDAVIS (800-482-3284)

Education
M.D., UC Davis, Davis CA 1991
B.S., Biological Sciences, UC Davis, Davis CA 1987

Internships
Internal Medicine, UC Davis, Davis CA 1991-1992

Residency
Internal Medicine, UC Davis, Davis CA 1992-1995

Fellowships
Hematology/Oncology, UC Davis Medical Center, Sacramento CA 1995-1998

Board Certifications
American Board of Internal Medicine
American Board of Internal Medicine, Hematology and Oncology
American Board of Internal Medicine, Medical Oncology, 2011

Honors and Awards
Award for "Bioethics Consultation" service provided to the the UC Davis Health Medical Staff Office, UC Davis Comprehensive Cancer Center, 2017
Honored for Expanding the WeCARE! Blood Cancer Peer Navigator Program into Cancer Care Network, UC Davis Comprehensive Cancer Center, 2015

UCDAVIS HEALTH

Scott Douglas Christensen, M.D.

Chief Resident, Department of Internal Medicine, UC Davis Medical Center, 1994, 1995
Alpha Omega Alpha, UC Davis, 1992

Select Recent Publications

For a comprehensive list of Dr. Christensen's publications, please click here (opens new window).

Semrad TJ, Kim EJ, Gong IY, Li T, Christensen S, Arora M, Riess JW, Gandara DR, Kelly K. Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2021 Aug;88(2):335-341. doi:10.1007/s00280-021-04293-3. Epub 2021 May 15. PMID:33993383.

Shi VY, Tran K, Patel F, Leventhal J, Konia T, Fung MA, Wilken R, Garcia MS, Fitzmaurice SD, Joo J, Monjazeb AM, Burrall BA, King B, Martinez S, Christensen SD, Maverakis E. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series. J Am Acad Dermatol. 2015 Oct;73(4):645-54. doi:10.1016/j.jaad.2015.06.060. Epub 2015 Aug 7.

Eroglu Z, Tawbi HA, Hu J, Guan M, Frankel PH, Ruel NH, Wilczynski S, Christensen S, Gandara DR, Chow WA. A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas. Br J Cancer. 2015 May 12;112(10):1644-51. doi:10.1038/bjc.2015.126. Epub 2015 Apr 21.

Canter RJ, Borys D, Olusanya A, Li CS, Lee LY, Boutin RD, Christensen SD, Tamurian RM, Monjazeb AM. Phase I Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients with Locally Advanced Soft Tissue Sarcoma of the Extremity. Ann Surg Oncol. 2014 May;21(5): 1616-1623. Published online 2014 Feb 20. doi:10.1245/s10434-014-3543-7.

Gadgeel SM, Lew DL, Synold TW, LoRusso P, Chung V, Christensen SD, Smith DC, Kingsbury L, Hoering A, Kurzrock R. Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. Cancer Chemother Pharmacol. 2013 Nov;72(5): 1089-96. doi:10.1007/s00280-013-2297-4. Epub 2013 Sep 22.

UCDAVIS HEALTH

Scott Douglas Christensen, M.D.

Wasif N, Smith CA, Tamurian RM, Christensen SD, Monjazeb AM, Martinez SR, Canter RJ. Influence of physician specialty on treatment recommendations in the multidisciplinary management of soft tissue sarcoma of the extremities. JAMA Surg. 2013 Jul;148(7):632-9. doi: 10.1001/jamasurg.2013.113.

Li T, Christensen SD, Frankel PH, Margolin KA, Agarwala SS, Luu T, Mack PC, Lara PN, Gandara DR. A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial. Invest New Drugs. 2012 Apr;30(3):741-8. doi:10.1007 /s10637-010-9562-8. Epub 2010 Oct 22.

Heifetz LJ, Christensen SD, Devere-White RW, Meyers FJ. A model for rural oncology. J Oncol Pract. 2011 May;7(3):168-71. doi:10.1200/JOP.2010.000167.

Davies AM, Ho C, Metzger AS, Beckett LA, Christensen S, Tanaka M, Lara PN, Lau DH, Gandara DR. Phase I Study of Two Different Schedules of Bortezomib and Pemetrexed in Advanced Solid Tumors with Emphasis on Non-small Cell Lung Cancer. J Thoracic Oncol. 2007 Dec;2(12):1112-1116. doi:10.1097/JTO.0b013e31815ba7d0.

© 2024 UC Regents

UCDAVIS HEALTH